0950.HK - Lee's Pharmaceutical Holdings Limited

HKSE - HKSE Delayed Price. Currency in HKD
10.760
-1.120 (-9.43%)
At close: 4:08PM HKT
Stock chart is not supported by your current browser
Previous Close11.880
Open11.880
Bid10.700 x 0
Ask10.760 x 0
Day's Range10.500 - 11.880
52 Week Range6.010 - 14.700
Volume3,312,000
Avg. Volume1,673,810
Market Cap6.37B
Beta1.83
PE Ratio (TTM)27.32
EPS (TTM)0.394
Earnings DateAug 22, 2018 - Aug 27, 2018
Forward Dividend & Yield0.10 (0.88%)
Ex-Dividend Date2018-05-21
1y Target Est13.83
  • Reuters5 days ago

    BRIEF-Lee's Pharmaceutical Says Gets Approval For Conducting Clinical Trials For TG02 From China FDA

    June 14 (Reuters) - Lee's Pharmaceutical Holdings Ltd : * CHINA FOOD AND DRUG ADMINISTRATION GRANTED APPROVAL FOR CONDUCTING CLINICAL TRIALS FOR TG02 Source text for Eikon: Further company coverage:

  • Reuters26 days ago

    BRIEF-Lee's Pharmaceutical Posts Q1 Profit Attributable Of HK$70.2 Mln

    May 24 (Reuters) - Lee's Pharmaceutical Holdings Ltd : * Q1 PROFIT ATTRIBUTABLE HK$70.2 MILLION VERSUS HK$46.4 MILLION * QTRLY REVENUE HK$281.905 MILLION VERSUS HK$226.200 MILLION Source text for Eikon: ...

  • What Investors Should Know About Lee’s Pharmaceutical Holdings Limited’s (HKG:950) Financial Strength
    Simply Wall St.last month

    What Investors Should Know About Lee’s Pharmaceutical Holdings Limited’s (HKG:950) Financial Strength

    Lee’s Pharmaceutical Holdings Limited (SEHK:950) is a small-cap stock with a market capitalization of HK$6.73B. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • Reuters3 months ago

    BRIEF-Lee's Pharmaceutical Says ‍FY Profit Attributable HK$232.6 Million

    March 22 (Reuters) - Lee's Pharmaceutical Holdings Ltd : * FY REVENUE HK$1.01 BILLION, UP 8.5 PERCENT * ‍FINAL DIVIDEND OF HK7.0 CENTS PER ORDINARY SHARE​ * ‍FY PROFIT ATTRIBUTABLE HK$232.6 MILLION VERSUS ...

  • GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant
    PR Newswire4 months ago

    GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

    YONGIN, South Korea, Feb. 14, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (006280.KS), a South Korean biopharmaceutical company, and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm") (0950.HK) today announced that they have entered into an agreement granting Lee's Pharm exclusive rights to develop and commercialise GCC-4401C, GC Pharma's investigational oral Factor Xa inhibitor anticoagulant which currently completed Phase I clinical development in the U.S. for the prevention and treatment of thromboembolic disease.

  • PR Newswire4 months ago

    GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

    YONGIN, South Korea, Feb. 13, 2018 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (006280.KS), a South Korean biopharmaceutical company, and Lee's Pharmaceutical (HK) Limited, a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm") (0950.HK) today announced that they have entered into an agreement granting Lee's Pharm exclusive rights to develop and commercialise GCC-4401C, GC Pharma's investigational oral Factor Xa inhibitor anticoagulant which currently completed Phase I clinical development in the U.S. for the prevention and treatment of thromboembolic disease.

  • CNW Group4 months ago

    GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

    GC Pharma and Lee's Pharm Enter into China Licensing Agreement to Develop and Commercialise GCC-4401C, an Investigational Anticoagulant

  • Reuters5 months ago

    BRIEF-Lee's Pharmaceutical Holdings Says China FDA Grants Unit Approval For Clinical Trials

    Jan 29 (Reuters) - Lee's Pharmaceutical Holdings Ltd : * CHINA FDA GRANTS UNIT APPROVAL FOR CLINICAL TRIALS FOR ITS RECOMBINANT HUMAN ANTI-PD-L1 MONOCLONAL ANTIBODY INJECTION Source text for Eikon: Further ...

  • Reuters6 months ago

    BRIEF-Lee's Pharmaceutical Says ‍Zhaoke Pharmaceutical & Zhaoke Oncology Entered Agreement​

    Dec 29 (Reuters) - Lee's Pharmaceutical Holdings Ltd : * ‍ZHAOKE PHARMACEUTICAL & ZHAOKE ONCOLOGY ENTERED INTO SALE AND PURCHASE AGREEMENT​ * UNDER DEAL, ‍ZHAOKE ONCOLOGY WILL PURCHASE ZHAOKE GUANGZHOU​ ...

  • Windtree Successfully Completes Financial Restructuring Program
    PR Newswire8 months ago

    Windtree Successfully Completes Financial Restructuring Program

    WARRINGTON, Pa. and SHATIN, HONG KONG, Nov. 1, 2017 /PRNewswire/ -- Windtree Therapeutics, Inc. (WINT), a biotechnology company focused on developing aerosolized KL4 surfactant therapies for respiratory diseases, and LPH Investments Limited ("LPHIL"), a wholly-owned subsidiary of Lee's Pharmaceutical Holdings Limited ("Lee's Pharm," SEHK Stock Code: 0950), today announced that they have completed a financial restructuring of Windtree that includes a purchase by Lee's Pharm via LPHIL of $10 million of Windtree's common stock, giving Lee's Pharm a controlling interest in Windtree, and a simultaneous restructuring and retirement of $25 million of long-term debt under the 2013 secured loan facility agreement between Windtree and affiliates of Deerfield Management Company, L.P. ("Deerfield"). The completion of these transactions improves Windtree's balance sheet and better positions the Company to raise the capital needed to fund continued development of AEROSURF® for respiratory distress syndrome (RDS) and potentially its pipeline of surfactant products utilizing its proprietary KL4 surfactant and aerosol device technologies.

  • PR Newswire11 months ago

    SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer

    SEOUL, Korea and SAN FRANCISCO and HONG KONG, July 21, 2017 /PRNewswire/ -- SillaJen, Inc., (215600.KQ), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and Lee's Pharmaceutical Holdings Ltd. (0950.HK), a research based biopharmaceutical company, announced approval (Approval No. 2017L04441) by the China Food and Drug Administration (CFDA) to conduct a Phase 3 clinical trial for advanced liver cancer using its oncolytic immunotherapy called Pexa-Vec (formerly JX-594), the PHOCUS study. SillaJen and Lee's Pharmaceutical participated in a first of its kind Chinese Center for Drug Evaluation advisory committee meeting for this approval, which was held earlier this year to promote transparency in the China drug development process.  At the end of the meeting, the committee voted, and it was announced by the chairman of the advisory committee, that the trial had been approved to be conducted in China.